Viridian shareholders approve 8M-share increase in equity plan in close vote

Viridian Therapeutics, Inc.\DE

Stockholders narrowly approved amendment to increase equity plan shares by 8,000,000 (35.3M for, 35.1M against).
Three Class I directors elected: Jeff Ajer, Chris Cain, Sarah Gheuens.
Ratification of KPMG as auditor, advisory say-on-pay, and 2025 ESPP all passed.
Close 49.8% opposition on equity plan reflects significant shareholder dissent.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.